AT500848B1 - Humanisierte anti-erbb2-antikörper - Google Patents

Humanisierte anti-erbb2-antikörper Download PDF

Info

Publication number
AT500848B1
AT500848B1 AT0911000A AT91102000A AT500848B1 AT 500848 B1 AT500848 B1 AT 500848B1 AT 0911000 A AT0911000 A AT 0911000A AT 91102000 A AT91102000 A AT 91102000A AT 500848 B1 AT500848 B1 AT 500848B1
Authority
AT
Austria
Prior art keywords
antibody
erbb2
cancer
quot
cells
Prior art date
Application number
AT0911000A
Other languages
German (de)
English (en)
Other versions
AT500848A1 (de
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22495168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT500848(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AT500848A1 publication Critical patent/AT500848A1/de
Application granted granted Critical
Publication of AT500848B1 publication Critical patent/AT500848B1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT0911000A 1999-06-25 2000-06-23 Humanisierte anti-erbb2-antikörper AT500848B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14131699P 1999-06-25 1999-06-25
PCT/US2000/017366 WO2001000245A2 (en) 1999-06-25 2000-06-23 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Publications (2)

Publication Number Publication Date
AT500848A1 AT500848A1 (de) 2006-04-15
AT500848B1 true AT500848B1 (de) 2008-01-15

Family

ID=22495168

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0911000A AT500848B1 (de) 1999-06-25 2000-06-23 Humanisierte anti-erbb2-antikörper
AT00943115T ATE437655T1 (de) 1999-06-25 2000-06-23 Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00943115T ATE437655T1 (de) 1999-06-25 2000-06-23 Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper

Country Status (32)

Country Link
EP (2) EP1189641B1 (en])
JP (2) JP4283474B2 (en])
KR (2) KR100850389B1 (en])
CN (4) CN101121021B (en])
AR (1) AR024464A1 (en])
AT (2) AT500848B1 (en])
AU (2) AU784045B2 (en])
BE (1) BE2013C020I2 (en])
BR (2) BRPI0012198B8 (en])
CA (2) CA2727172A1 (en])
CH (1) CH694589A5 (en])
CY (2) CY1109525T1 (en])
CZ (1) CZ299702B6 (en])
DE (2) DE10084743T1 (en])
DK (1) DK1189641T5 (en])
ES (1) ES2329437T3 (en])
FR (1) FR13C0016I2 (en])
GB (1) GB2368796B (en])
GE (1) GEP20104998B (en])
HU (1) HU226742B1 (en])
IL (3) IL146954A0 (en])
LU (1) LU92164I2 (en])
MX (1) MXPA01013458A (en])
NO (3) NO328377B1 (en])
NZ (2) NZ531426A (en])
PL (2) PL203326B1 (en])
PT (1) PT1189641E (en])
RU (2) RU2270029C2 (en])
SI (3) SI2283866T1 (en])
TR (1) TR200103756T2 (en])
WO (1) WO2001000245A2 (en])
ZA (2) ZA200109786B (en])

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
IL147241A0 (en) * 1999-06-25 2002-08-14 Genentech Inc METHODS OF TREATMENT USING ANTI ErbB ANTIBODY-MAYTANSINOID CONJUGATES
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN101121021B (zh) * 1999-06-25 2011-12-07 杰南技术公司 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
KR20090024308A (ko) 1999-08-27 2009-03-06 제넨테크, 인크. 항-ErbB2 항체 투여 치료 방법
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
SI1282443T1 (sl) 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
CH696871A5 (de) * 2001-10-26 2008-01-15 Altarex Medical Corp Verwendung eines chemotherapeutischen Arzneimittels und einer Zusammensetzung, die ein Bindemittel umfasst, zur Herstellung eines Medikamentes zur Krankheitsbehandlung.
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
JP2005535297A (ja) * 2002-04-11 2005-11-24 アムジェン インコーポレイテッド Her−2レセプターチロシンキナーゼ分子およびその使用
ITTO20020340A1 (it) * 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
US7198899B2 (en) 2002-06-03 2007-04-03 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
NO340576B1 (no) * 2002-07-11 2017-05-15 Hoffmann La Roche Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
BR0312664A (pt) 2002-07-18 2005-05-03 Helix Biopharma Corp Composição farmacêutica e uso da enzima urease para a fabricação de um medicamento para o tratamento de células cancerìgenas em um indivìduo
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
EP1546203B1 (en) 2002-08-01 2012-06-20 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CN101972478B (zh) * 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
WO2005003325A2 (en) * 2003-03-11 2005-01-13 Dana Farber Cancer Institute Inhibition of viral pathogenesis
CA2523142A1 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
WO2005020923A2 (en) * 2003-08-29 2005-03-10 Cedars-Sinai Medical Center Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
SG146644A1 (en) * 2003-09-18 2008-10-30 Raven Biotechnologies Inc Kid3 and kid3 antibodies that bind thereto
JP2007512324A (ja) * 2003-11-28 2007-05-17 ミトラ、メディカル、アクチボラグ Erb抗原のターゲッティング
RU2402568C2 (ru) * 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20190035967A (ko) 2004-07-22 2019-04-03 제넨테크, 인크. Her2 항체 조성물
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20070085855A (ko) * 2004-12-07 2007-08-27 제넨테크, 인크. Her 억제제를 이용한 치료를 위한 환자 선택 방법
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
KR101164820B1 (ko) 2005-09-22 2012-07-12 삼성전자주식회사 디스플레이장치
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2009527227A (ja) 2006-02-17 2009-07-30 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
EP2035039A2 (en) * 2006-06-05 2009-03-18 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
SI2056874T1 (sl) 2006-08-21 2012-12-31 F. Hoffmann-La Roche Ag Terapija tumorjev s protitelesom proti vegf
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
NZ601022A (en) * 2006-10-12 2014-09-26 Chugai Pharmaceutical Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CA2677108A1 (en) * 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US20100254996A1 (en) * 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
CA3160831A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
ES2689274T3 (es) 2008-01-03 2018-11-13 The Scripps Research Institute Dirección de anticuerpos mediante un dominio de reconocimiento modular
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-cd79b 항체 및 면역접합체 및 사용 방법
ES2544682T3 (es) 2008-03-14 2015-09-02 Genentech, Inc. Variaciones genéticas asociadas con la resistencia a fármacos
KR102784999B1 (ko) * 2008-03-18 2025-03-21 제넨테크, 인크. 항-her2 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
JP2011521009A (ja) 2008-05-23 2011-07-21 シワ コーポレイション 再生を促進させる方法、組成物及び装置
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
PL3903829T3 (pl) 2009-02-13 2023-08-14 Immunomedics, Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
CN102356092B (zh) 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
JP6132548B2 (ja) 2009-04-01 2017-05-24 ジェネンテック, インコーポレイテッド 抗FcRH5抗体および免疫接合体および使用方法
WO2010115553A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CN102498206A (zh) 2009-08-11 2012-06-13 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
CA2771086A1 (en) * 2009-08-15 2011-02-24 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
PL2473617T3 (pl) 2009-09-01 2020-06-29 F. Hoffmann-La Roche Ag Ulepszone oczyszczanie białka poprzez zmodyfikowaną elucję z białka A
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PL2486141T3 (pl) 2009-10-07 2018-07-31 Macrogenics, Inc. Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów
TW201122101A (en) * 2009-10-28 2011-07-01 Facet Biotech Corp Anti-EGFR antibodies and their uses
CN105274170A (zh) 2009-11-05 2016-01-27 弗·哈夫曼-拉罗切有限公司 分泌异源多肽的方法和组合物
ES2655737T3 (es) 2009-11-13 2018-02-21 Daiichi Sankyo Europe Gmbh Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
JP5742714B2 (ja) * 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び/又は予防用医薬組成物
MY160556A (en) * 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
KR102218495B1 (ko) 2010-03-22 2021-02-19 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
DK2576580T3 (en) 2010-05-28 2016-10-17 Hoffmann La Roche LOWERING THE lactate AND INCREASE polypeptide production by downregulation of the expression of lactate dehydrogenase, and PYRUVATDEHYDROGENASEKINASE
NZ602840A (en) 2010-06-03 2014-11-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
SI3586826T1 (sl) 2010-06-24 2021-09-30 F. Hoffmann-La Roche Ag Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
US20140162317A1 (en) 2010-12-21 2014-06-12 Roberto Falkenstein Isoform entriched antibody preparation and method for obtaining it
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN103384681B (zh) 2010-12-23 2018-05-18 霍夫曼-拉罗奇有限公司 结合剂
KR101928116B1 (ko) 2011-01-31 2018-12-11 노파르티스 아게 신규 헤테로시클릭 유도체
CN103649326B (zh) * 2011-03-08 2016-08-17 宾夕法尼亚大学理事会 用于治疗和诊断用途的抗体样蛋白
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
UA123092C2 (uk) 2011-10-14 2021-02-17 Дженентек, Інк. Спосіб неоад'ювантного лікування her2-позитивного раку молочної залози на ранній стадії у пацієнта
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
JP2015500638A (ja) 2011-11-30 2015-01-08 ジェネンテック, インコーポレイテッド 癌におけるerbb3変異
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CA2859376C (en) 2011-12-22 2022-04-19 Genentech, Inc. Use of ion exchange chromatography for improving downstream chromatography steps for purification of antibodies
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP2809805A1 (en) 2012-01-31 2014-12-10 SmithKline Beecham (Cork) Limited Method of treating cancer
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
MX2014011500A (es) 2012-03-27 2014-12-05 Genentech Inc Diagnosticos y tratamientos relacionados a inhibidores her3.
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
KR101505157B1 (ko) * 2012-05-08 2015-03-24 주식회사 종근당 항―ErbB2 항체 변이체
SG10201608469RA (en) 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
BR112015012644A2 (pt) 2012-11-30 2017-12-19 Hoffmann La Roche método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
WO2014108858A1 (en) 2013-01-10 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Fatty acid synthase inhibitors
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
CN104628846B (zh) 2013-11-06 2019-12-06 三生国健药业(上海)股份有限公司 重组蛋白质的纯化方法
SMT202100394T1 (it) 2013-11-19 2021-09-14 Remegen Co Ltd Anticorpo anti-her2 e relativo coniugato
RS66775B1 (sr) * 2013-11-27 2025-05-30 Zymeworks Bc Inc Bispecifični antigen-vezujući konstrukti koji targetiraju her2
SI3076969T1 (sl) 2013-12-06 2021-12-31 Novartis Ag Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze
RS66412B1 (sr) 2014-01-31 2025-02-28 Daiichi Sankyo Co Ltd Anti-her2 antitelo-lek konjugat
US20160361309A1 (en) 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
EP3116999B1 (en) 2014-03-14 2021-09-15 F. Hoffmann-La Roche AG Methods and compositions for secretion of heterologous polypeptides
ES2819863T3 (es) 2014-04-11 2021-04-19 Medimmune Llc Anticuerpos contra HER2 biespecíficos
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
MX391802B (es) 2014-09-19 2025-03-11 Siwa Corp Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
FI3223848T3 (fi) 2014-11-27 2025-02-28 Zymeworks Bc Inc Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ErbB2 항체 변이체
WO2016179707A1 (en) * 2015-05-13 2016-11-17 Zymeworks Inc. Antigen-binding constructs targeting her2
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
RU2766209C2 (ru) * 2015-10-13 2022-02-09 Сива Корпорейшн Антитела к age и способы их применения
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CA3006934A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CN105646704B (zh) * 2015-12-28 2019-11-15 广西医科大学 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
JP6722293B2 (ja) 2016-02-19 2020-07-15 シワ コーポレーション 終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
KR20180119570A (ko) * 2016-03-15 2018-11-02 메리맥 파마슈티컬즈, 인크. 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
EP3443007A1 (en) 2016-04-15 2019-02-20 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
SG11201810032PA (en) * 2016-05-12 2018-12-28 Agency Science Tech & Res Anti-erbb-2 antibodies and uses thereof
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
KR20230158641A (ko) 2016-10-07 2023-11-20 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
JP7069476B2 (ja) * 2017-01-06 2022-05-18 博奥信生物技▲術▼(南京)有限公司 ErbB2抗体およびその使用
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
KR102417583B1 (ko) 2017-03-02 2022-07-07 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
KR20200044044A (ko) 2017-08-23 2020-04-28 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
KR102816741B1 (ko) 2017-08-31 2025-06-04 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
CA3101906A1 (en) 2018-05-28 2019-12-05 Daiichi Sankyo Company, Limited Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
CN112703000B (zh) 2018-07-23 2024-05-31 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
CN112566942A (zh) 2018-07-25 2021-03-26 第一三共株式会社 用于制造抗体-药物缀合物的有效方法
CN112533958B (zh) 2018-07-27 2024-11-15 第一三共株式会社 识别抗体-药物缀合物的药物部分的蛋白
SG11202100947SA (en) 2018-07-31 2021-03-30 Daiichi Sankyo Co Ltd Treatment of metastatic brain tumor by administration of antibody-drug conjugate
BR112021001750A2 (pt) 2018-08-06 2021-04-27 Daiichi Sankyo Company, Limited composição farmacêutica
TW202016317A (zh) 2018-08-23 2020-05-01 日商第一三共股份有限公司 抗體藥物結合物之感受性標記
IL281804B1 (en) 2018-09-25 2025-05-01 Absci Llc Protein purification methods
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
BR112021011119A2 (pt) 2018-12-11 2022-01-25 Daiichi Sankyo Co Ltd Composição farmacêutica
US11596632B2 (en) 2018-12-19 2023-03-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
US20220098303A1 (en) 2019-02-01 2022-03-31 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
MX2021012032A (es) 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
CN112007169B (zh) * 2019-05-30 2022-03-08 湖南大学 一种核酸适配体药物偶联物及其制备方法和用途
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
MA56397A (fr) 2019-06-26 2022-05-04 Glaxosmithkline Ip Dev Ltd Protéines de liaison à l'il1rap
CN110551214A (zh) * 2019-08-27 2019-12-10 杨澜 一种人源化抗Periostin单克隆抗体、及其制备方法和应用
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.
EP4096718A1 (en) 2020-01-28 2022-12-07 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
TW202216208A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atr抑制劑之組合
JP2023542065A (ja) 2020-06-24 2023-10-05 アストラゼネカ ユーケー リミテッド 抗体-薬物複合物及びcdk9阻害剤の組み合わせ
JP2023539715A (ja) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体-薬物コンジュゲートとatm阻害剤との組合わせ
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
EP4183420A4 (en) 2020-07-20 2025-03-05 Daiichi Sankyo Company, Limited COMBINATION OF (ANTI-HER2 ANTIBODY) DRUG CONJUGATE AND HER DIMERIZATION INHIBITOR
CA3195117A1 (en) 2020-10-09 2022-04-14 Jerome Thomas Mettetal Ii Combination of antibody-drug conjugate and parp1 selective inhibitor
CN116916919A (zh) 2020-11-11 2023-10-20 第一三共株式会社 抗体-药物缀合物与抗SIRPα抗体的组合
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
JP2025503511A (ja) 2021-12-28 2025-02-04 アストラゼネカ ユーケー リミテッド 抗体-薬物コンジュゲート及びrasg12c阻害剤の組み合わせ
KR20240141757A (ko) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 환경 응답성 마스킹 항체 및 그 이용
IL316421A (en) 2022-04-27 2024-12-01 Daiichi Sankyo Co Ltd Combination of an antibody-drug conjugate with an EZH1 and/or EZH2 inhibitor
EP4522658A1 (en) 2022-05-11 2025-03-19 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
EP4561635A1 (en) 2022-07-28 2025-06-04 AstraZeneca UK Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1998017797A1 (en) * 1996-10-18 1998-04-30 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
WO1999031140A1 (en) * 1997-12-12 1999-06-24 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
IL74201A0 (en) 1984-01-30 1985-04-30 Icrf Patents Limited Polypeptides for the detection and control of mammalian cell growth
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
CA2129663C (en) 1992-02-06 2005-07-05 James S. Huston Biosynthetic binding protein for cancer marker
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
DE69326937T2 (de) 1993-03-24 2000-12-28 Berlex Biosciences, Richmond Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
CA2175893C (en) 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
ATE483733T1 (de) 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
BR9609743A (pt) 1995-07-27 1999-03-02 Genentech Inc Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
IL127892A0 (en) * 1996-07-12 1999-10-28 Genentech Inc Gamma-heregulin
ES2197359T3 (es) * 1996-08-12 2004-01-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y utilizacion de los mismos para disminuir los niveles de citocina.
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
DE60040981D1 (de) * 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
IL147241A0 (en) * 1999-06-25 2002-08-14 Genentech Inc METHODS OF TREATMENT USING ANTI ErbB ANTIBODY-MAYTANSINOID CONJUGATES
ATE355079T1 (de) * 1999-06-25 2006-03-15 Genentech Inc Behandlung von prostata-krebs mit anti-erbb2 antikörpern
CN101121021B (zh) * 1999-06-25 2011-12-07 杰南技术公司 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
KR20090024308A (ko) * 1999-08-27 2009-03-06 제넨테크, 인크. 항-ErbB2 항체 투여 치료 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5677171A (en) * 1988-01-12 1997-10-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
WO1998017797A1 (en) * 1996-10-18 1998-04-30 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
WO1999031140A1 (en) * 1997-12-12 1999-06-24 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Also Published As

Publication number Publication date
SI2283867T1 (sl) 2014-07-31
EP1189641B1 (en) 2009-07-29
KR20020068264A (ko) 2002-08-27
IL146954A (en) 2009-09-22
CA2376596A1 (en) 2001-01-04
RU2005132788A (ru) 2007-04-27
SI2283866T1 (sl) 2015-07-31
JP2009142280A (ja) 2009-07-02
AU784045B2 (en) 2006-01-19
AU2005242195A1 (en) 2006-01-12
FR13C0016I2 (fr) 2014-05-16
CZ299702B6 (cs) 2008-10-22
EP2112167A3 (en) 2010-12-22
GB0200506D0 (en) 2002-02-27
CY2013010I2 (el) 2015-08-05
CN101518653A (zh) 2009-09-02
NO2013005I2 (no) 2013-03-12
ATE437655T1 (de) 2009-08-15
AR024464A1 (es) 2002-10-02
GEP20104998B (en) 2010-06-10
EP1189641A2 (en) 2002-03-27
NO336040B1 (no) 2015-04-27
ES2329437T3 (es) 2009-11-26
PL352321A1 (en) 2003-08-11
ZA200110263B (en) 2003-02-26
DE10084743T1 (de) 2002-08-14
DK1189641T5 (da) 2011-04-11
AU5763200A (en) 2001-01-31
WO2001000245A3 (en) 2001-10-25
CA2727172A1 (en) 2001-01-04
IL146954A0 (en) 2002-08-14
NO20016329D0 (no) 2001-12-21
HU226742B1 (en) 2009-08-28
GB2368796B (en) 2004-08-04
CN101121021A (zh) 2008-02-13
PL204629B1 (pl) 2010-01-29
JP2003503366A (ja) 2003-01-28
NO20016329L (no) 2002-02-25
NO328377B1 (no) 2010-02-08
ZA200109786B (en) 2002-11-28
RU2430739C9 (ru) 2015-12-20
BR122014028365B8 (pt) 2021-07-06
RU2430739C2 (ru) 2011-10-10
DE60042648D1 (de) 2009-09-10
CY2013010I1 (el) 2015-08-05
PL203326B1 (pl) 2009-09-30
CN101121021B (zh) 2011-12-07
RU2270029C2 (ru) 2006-02-20
HUP0201695A2 (en) 2002-09-28
BRPI0012198B8 (pt) 2021-05-25
BE2013C020I2 (en]) 2019-08-21
AT500848A1 (de) 2006-04-15
CN101121750A (zh) 2008-02-13
NZ516830A (en) 2004-07-30
HK1044888A1 (en) 2002-11-08
PT1189641E (pt) 2009-11-04
EP2112167A2 (en) 2009-10-28
NO2013005I1 (no) 2013-04-02
KR20070094993A (ko) 2007-09-27
CN100340575C (zh) 2007-10-03
KR100850389B1 (ko) 2008-08-04
FR13C0016I1 (en]) 2013-04-12
GB2368796A (en) 2002-05-15
KR100797308B1 (ko) 2008-01-23
CY1109525T1 (el) 2014-08-13
SI1189641T1 (sl) 2009-12-31
BR0012198A (pt) 2002-04-02
DK1189641T3 (da) 2009-11-16
CN1370082A (zh) 2002-09-18
HUP0201695A3 (en) 2005-06-28
BR122014028365B1 (pt) 2020-01-28
CA2376596C (en) 2009-10-06
WO2001000245A2 (en) 2001-01-04
BRPI0012198B1 (pt) 2016-12-20
MXPA01013458A (es) 2002-07-30
CZ20014596A3 (cs) 2003-02-12
IL197359A0 (en) 2011-07-31
NZ531426A (en) 2005-10-28
NO20091792L (no) 2002-02-25
CN101518653B (zh) 2015-08-19
LU92164I2 (fr) 2013-05-07
TR200103756T2 (tr) 2002-06-21
AU2005242195B2 (en) 2009-06-11
JP4283474B2 (ja) 2009-06-24
CH694589A5 (de) 2005-04-15

Similar Documents

Publication Publication Date Title
AT500848B1 (de) Humanisierte anti-erbb2-antikörper
DE60033658T2 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
US7537931B2 (en) Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
US20070184055A1 (en) Treatment with anti-erbb2 antibodies
HK1044888B (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
HK1130502A (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies

Legal Events

Date Code Title Description
MK07 Expiry

Effective date: 20200623